{"id":"ibandronate-calcium-and-vitamin-d","safety":{"commonSideEffects":[{"rate":"5-15%","effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":"5-10%","effect":"Musculoskeletal pain"},{"rate":"3-7%","effect":"Headache"},{"rate":"<1%","effect":"Osteonecrosis of the jaw (rare)"},{"rate":"<1%","effect":"Atypical femoral fractures (rare)"}]},"_chembl":{"chemblId":"CHEMBL3989569","moleculeType":"Small molecule","molecularWeight":"359.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibandronate is a nitrogen-containing bisphosphonate that reduces bone turnover by inhibiting osteoclast activity and promoting osteoclast apoptosis. Calcium provides the mineral substrate for bone formation, and vitamin D enhances intestinal calcium absorption and regulates calcium-phosphate metabolism, together reducing fracture risk in osteoporosis.","oneSentence":"Ibandronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase, while calcium and vitamin D support bone mineralization and calcium homeostasis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:49.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis prevention and treatment in postmenopausal women"},{"name":"Bone loss associated with glucocorticoid therapy"}]},"trialDetails":[{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT04321837","phase":"PHASE2","title":"Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-02-05","conditions":"Osteoporosis, Postmenopausal","enrollment":60},{"nctId":"NCT06022237","phase":"NA","title":"Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-09-01","conditions":"Hepatic Osteodystrophy, Liver Cirrhosis","enrollment":80},{"nctId":"NCT05266261","phase":"NA","title":"Use of Ibandronate in Diabetic Patients","status":"COMPLETED","sponsor":"Yeouido St. Mary's Hospital","startDate":"2018-10-01","conditions":"Osteoporosis, Postmenopausal, Type 2 Diabetes","enrollment":121},{"nctId":"NCT00824993","phase":"PHASE3","title":"Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-12-09","conditions":"Hematological Malignancies","enrollment":78},{"nctId":"NCT00048061","phase":"PHASE3","title":"MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-04","conditions":"Post Menopausal Osteoporosis","enrollment":1609},{"nctId":"NCT00303485","phase":"PHASE4","title":"A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-02","conditions":"Post Menopausal Osteoporosis","enrollment":67},{"nctId":"NCT00683163","phase":"PHASE2, PHASE3","title":"PTH & Ibandronate Combination Study (PICS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-05","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT00551174","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Post-Menopausal Osteoporosis","enrollment":781},{"nctId":"NCT00423384","phase":"PHASE2, PHASE3","title":"Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.","status":"UNKNOWN","sponsor":"Smerud Medical Research International AS","startDate":"2007-01","conditions":"Renal Transplant","enrollment":130},{"nctId":"NCT00271713","phase":"PHASE4","title":"Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-03","conditions":"Osteoporosis, Postmenopausal","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ibandronate, calcium and vitamin D","genericName":"ibandronate, calcium and vitamin D","companyName":"Charite University, Berlin, Germany","companyId":"charite-university-berlin-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibandronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase, while calcium and vitamin D support bone mineralization and calcium homeostasis. Used for Osteoporosis prevention and treatment in postmenopausal women, Bone loss associated with glucocorticoid therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}